local_hospital

Fakultni Nemocnice Hradec Kralove

Address
lock Available on a paid plan

Urologic and Kidney Cancer Research

At Fakultni Nemocnice Hradec Kralove, research in urology and related oncology areas focuses on cancers of the urinary and male reproductive systems, especially renal cell carcinoma and prostate cancer. These studies are designed to compare new treatment approaches with current standards and to improve long-term outcomes for people with advanced or high-risk disease.

  • Advanced and metastatic renal cell carcinoma
  • High-risk localized or locally advanced prostate cancer
  • High-risk and locally advanced prostate cancer after surgery or radiation

The site is contributing to trials that evaluate whether newer therapies can better control disease progression, reduce recurrence, and improve survival in difficult-to-treat cancers.

Hematology and Lymphoma Studies

A major part of the clinical trial portfolio involves hematology and lymphoma research, with studies in chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, and Hodgkin lymphoma. These trials aim to test more effective treatment combinations, improve response rates, and support longer disease control in both newly diagnosed and relapsed settings.

  • Chronic lymphocytic leukemia and small lymphocytic lymphoma
  • Follicular lymphoma and marginal zone lymphoma
  • Diffuse large B-cell lymphoma and Hodgkin lymphoma

The research also includes efforts to refine treatment selection and improve outcomes after prior therapy, reflecting a strong focus on personalized blood cancer care.

Autoimmune, Inflammatory, and Neurologic Disorders

The site also supports trials in immune system diseases and nervous system diseases, including multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and juvenile idiopathic arthritis. These studies are aimed at understanding how newer therapies may reduce inflammation, improve symptoms, and help patients maintain function over time.

  • Relapsing and progressive multiple sclerosis
  • Psoriatic arthritis and axial spondyloarthritis
  • Crohn’s disease and juvenile idiopathic arthritis

This area of research includes both safety and effectiveness studies, with a clear emphasis on better disease control for chronic immune-mediated conditions.

Cardiovascular and Metabolic Disease Research

Clinical trials at the site cover important cardiovascular diseases and nutritional and metabolic diseases, including acute myocardial infarction, acute coronary syndrome, heart failure, atherosclerotic cardiovascular disease, and severe hypertriglyceridemia. The goal is to evaluate therapies that may lower cardiovascular risk, prevent recurrent events, and improve outcomes in people with inflammation-related heart disease.

  • Acute coronary syndrome and acute myocardial infarction
  • Heart failure with preserved or mildly reduced ejection fraction
  • Atherosclerotic cardiovascular disease and elevated lipoprotein(a)

These studies reflect a strong interest in prevention as well as treatment, particularly for patients at high risk of future cardiac complications.

Respiratory and Allergy-Related Trials

Research in respiratory tract diseases includes chronic obstructive pulmonary disease and different forms of asthma, along with hereditary angioedema as an immune-related condition. The studies are focused on whether newer treatments can reduce flare-ups, improve symptom control, and lessen dependence on long-term rescue or maintenance medicines.

  • Chronic obstructive pulmonary disease
  • Severe asthma and oral corticosteroid-dependent asthma
  • Hereditary angioedema

This part of the portfolio highlights practical goals such as better day-to-day breathing, fewer exacerbations, and improved quality of life.

Dermatology, Eye, and Other Specialty Areas

The site’s broader trial activity also includes skin and connective tissue diseases, eye diseases, and selected female urogenital diseases. Studies involve melanoma, psoriasis, macular edema, and endometrial cancer, showing a wide-ranging effort to assess new therapies and improve disease control across several specialties.

  • Melanoma and chronic plaque psoriasis
  • Macular edema secondary to retinal vein occlusion
  • Mismatch-repair deficient high-risk endometrial cancer

These trials are generally aimed at improving treatment effectiveness, delaying recurrence, or preserving vision and skin health in conditions with substantial impact on daily life.

Kidney, Blood, and Musculoskeletal Research

Additional work at Fakultni Nemocnice Hradec Kralove includes studies in hemic and lymphatic diseases, congenital and hereditary disorders, and digestive system and oral physiological phenomena. Important topics include primary IgA nephropathy, Alport syndrome, immune thrombocytopenia, and knee cartilage defects. The purpose of these trials is to explore new treatment options and better support for chronic or inherited conditions.

  • Primary IgA nephropathy and Alport syndrome
  • Immune thrombocytopenia
  • Knee cartilage defect repair

This research demonstrates a broad clinical interest in both organ-specific disease management and regenerative approaches.

Site Overview

assignment
312
connected trials
corporate_fare
114
sponsors
science
413
IMPs

Activity Indicator

Last 6 months

25
Trials started
-19% vs previous period.
31
Trials started 6–12 months ago
312
Total trials linked
Highly Active
trending_downDeclining-19%
4
5
7
3
6
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 30 therapeutic areas and 15 of 413 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 401 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
129
Sponsors (total)
114
Active sponsors
68

Sponsor Network

Top 68 by active trials.

lock +67 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +43 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 634 other sites in Czechia

description
Trial volume
312
Outperforms 100% of sites
public
Therapeutic diversity
31areas
Outperforms 100% of sites
groups
Sponsor diversity
114sponsors
Outperforms 100% of sites

Therapeutic Area Benchmark — Czechia

Select a therapeutic area to compare against other sites in Czechia.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Czechia

Market Share

Country: Czechia

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Fakultni Nemocnice Hradec Kralove

lock Showing 1 of 312 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein OcclusionBayer AGPhase IIINot RecruitingSep 2023May 2025

IMP list

lock Showing 1 of 413 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Rituximab30Unknown2017-07-142025-11-03

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.